Skip to main content

Juan Ignacio Esteban Mur

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Juan Ignacio Esteban Mur

Institutions of which they are part

Main researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Aplicación de la tecnología de secuenciación masiva para optimizar el coste-efectividad del tratamiento de la hepatitis C (VHC) en la era de los inhibidores de acción directa (DAAs).

IP: Juan Ignacio Esteban Mur
Collaborators: Lluís Viladomiu Catà, Lluis Castells Fusté, Josep Quer Sivila, Damir Garcia Cehic, Cristina Dopazo Taboada
Funding agency: Instituto de Salud Carlos III
Funding: 192692.5
Reference: PI13/00456
Duration: 01/01/2014 - 31/01/2017

Estudio de quasiespecies de los virus de la hepatits B y C (VHB y VHC) y de polimorfismos genómicos asociados a respuesta al tratamiento antiviral por pirosecuenciación

IP: Juan Ignacio Esteban Mur
Collaborators: -
Funding agency: CENTRO PARA EL DESARROLLO TÉCNICO INDUSTRIAL (CDTI
Funding: 875000
Reference: CDTI-2010-01
Duration: 01/03/2010 - 30/04/2013

Expansión/restauración funcional de células CD4 NS3 específicas autólogas en la prevención de la recurrencia VHC post-trasplante hepático: optimización del proceso para uso clínico

IP: Juan Ignacio Esteban Mur
Collaborators: Itxarone Izaskun Bilbao Aguirre, Lluis Castells Fusté, Silvia Sauleda Oliveras, Isabel Campos Varela, Marta Bes Maijo, Maria Madeleine Piron
Funding agency: Instituto de Salud Carlos III
Funding: 135520
Reference: PI10/01505
Duration: 01/01/2011 - 30/06/2014

Unitat de Recerca en Malalties Hepatobiliars

IP: Joan Genescà Ferrer
Collaborators: Immaculada Raurell Saborit, Antonio González Fernández, Lluis Castells Fusté, Silvia Sauleda Oliveras, Lluís Palenzuela Díaz, Maria Buti Ferret, Josep Quer Sivila, Maria Nieves Martell Pérez-Alcalde, Juan Ignacio Esteban Mur, David Tabernero Caellas
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 54080
Reference: 2009 SGR 383
Duration: 01/01/2010 - 30/04/2014

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

Related professionals

Anna Sanjuan Viaplana

Anna Sanjuan Viaplana

Medium Grade Technician
Statistics and Bioinformatics Unit (UEB)
Preclinical Core Facilities
External Strategy Directorate
Read more
Garcia Blanco, Alejandra

Garcia Blanco, Alejandra

Research technician
Neurodegenerative Diseases
Read more
Joan Compte Barrón

Joan Compte Barrón

Predoctoral researcher
Neurodegenerative Diseases
Read more
Piqué Ponti, Julia

Piqué Ponti, Julia

Predoctoral researcher
Childhood Cancer and Blood Disorders
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.